MET and cancer: This type of cancer unfortunately has limited therapeutic options and tyrosine kinases inhibitors trials gave mixed results, somewhat due to suboptimal patient selection.89Zr‐onartuzumab was used to show that in PDAC otherwise resistant to c‐Met kinase activity inhibitors, immuno‐PET can diagnose potential patients for targeted radioligand therapy.89Zr‐onartuzumab was evaluated against Suit2, Capan2, BxPC3, and MIA PaCa‐2, all tumors resistant to tyrosine kinases inhibitors, despite overexpression of c‐Met.